Gyre Therapeutics Inc. Asset Resilience Ratio
Gyre Therapeutics Inc. asset resilience ratio. Gyre Therapeutics Inc. (GYRE) has an Asset Resilience Ratio of 7.60% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Gyre Therapeutics Inc. to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Gyre Therapeutics Inc. (2006–2025)
Asset resilience ratio of Gyre Therapeutics Inc. from 2006 to 2025. This chart shows how Gyre Therapeutics Inc.'s Asset Resilience Ratio has changed over time. Read GYRE total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Gyre Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Gyre Therapeutics Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $12.31 Million | 7.6% |
| Total Liquid Assets | $12.31 Million | 7.60% |
Asset Resilience Insights
- Limited Liquidity: Gyre Therapeutics Inc. maintains only 7.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gyre Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Gyre Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Gyre Therapeutics Inc. Asset Resilience Ratio by Year (2006–2025)
Gyre Therapeutics Inc. asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Gyre Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.24% | $15.36 Million | $166.13 Million | -2.61pp |
| 2024-12-31 | 11.85% | $14.86 Million | $125.41 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $116.54 Million | -- |
| 2022-12-31 | 12.50% | $10.60 Million | $84.75 Million | +8.00pp |
| 2021-12-31 | 4.50% | $2.50 Million | $55.66 Million | -47.16pp |
| 2020-12-31 | 51.66% | $48.99 Million | $94.85 Million | -10.74pp |
| 2019-12-31 | 62.40% | $61.50 Million | $98.55 Million | -8.78pp |
| 2018-12-31 | 71.18% | $88.91 Million | $124.92 Million | +25.70pp |
| 2017-12-31 | 45.48% | $17.97 Million | $39.51 Million | +27.63pp |
| 2016-12-31 | 17.85% | $6.80 Million | $38.09 Million | +12.96pp |
| 2015-12-31 | 4.89% | $3.40 Million | $69.52 Million | -40.60pp |
| 2014-12-31 | 45.50% | $50.95 Million | $112.00 Million | +19.55pp |
| 2013-12-31 | 25.94% | $37.84 Million | $145.87 Million | +3.41pp |
| 2012-12-31 | 22.53% | $42.72 Million | $189.58 Million | -11.45pp |
| 2011-12-31 | 33.98% | $87.72 Million | $258.13 Million | +15.65pp |
| 2010-12-31 | 18.33% | $48.17 Million | $262.79 Million | +9.83pp |
| 2009-12-31 | 8.50% | $27.16 Million | $319.38 Million | -29.20pp |
| 2008-12-31 | 37.71% | $37.16 Million | $98.55 Million | +3.72pp |
| 2007-12-31 | 33.99% | $33.64 Million | $98.96 Million | +18.69pp |
| 2006-12-31 | 15.29% | $12.45 Million | $81.37 Million | -- |
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in th… Read more